Literature DB >> 8437705

Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease.

I Tooyama1, T Kawamata, D Walker, T Yamada, K Hanai, H Kimura, M Iwane, K Igarashi, E G McGeer, P L McGeer.   

Abstract

Basic fibroblast growth factor (bFGF) has a neurotrophic effect on mesencephalic dopaminergic neurons in vitro and in vivo. To explore whether an abnormality in bFGF expression occurs in Parkinson's disease (PD), we examined the substantia nigra (SN) of six PD and eight control cases immunohistochemically using a monoclonal antibody to bFGF. The mean number of melanin-positive neurons in sections of PD SN was 30.3% of the control mean, but the number of bFGF-immunopositive neurons was only 4.7% of the control mean. bFGF-immunoreactivity was present in only 8.2% of PD, but in 93.7% of control melanin-positive neurons. These results suggest a profound depletion of bFGF in surviving dopaminergic neurons of the SN in PD, and this depletion may be related to the disease process.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437705     DOI: 10.1212/wnl.43.2.372

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

1.  Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease.

Authors:  J Garcia de Yebenes; J Yebenes; M A Mena
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 2.  Nonviral gene transfection nanoparticles: function and applications in the brain.

Authors:  Indrajit Roy; Michal K Stachowiak; Earl J Bergey
Journal:  Nanomedicine       Date:  2008-03-03       Impact factor: 5.307

3.  Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  J Peng; L Xie; K Jin; D A Greenberg; J K Andersen
Journal:  Neuroscience       Date:  2008-03-07       Impact factor: 3.590

4.  Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways.

Authors:  Shih-Ling Hsuan; Heather M Klintworth; Zhengui Xia
Journal:  J Neurosci       Date:  2006-04-26       Impact factor: 6.167

Review 5.  Glutamate and neurotrophic factors in neuronal plasticity and disease.

Authors:  Mark P Mattson
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 6.  Neurotrophic factors for the investigation and treatment of movement disorders.

Authors:  Justo Garcia De Yébenes; Marina Sánchez; Maria Angeles Mena
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

7.  Pick's disease immunohistochemistry: new alterations and Alzheimer's disease comparisons.

Authors:  O Yasuhara; A Matsuo; I Tooyama; H Kimura; E G McGeer; P L McGeer
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

Review 8.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Strain difference in the up-regulation of FGF-2 protein following a neurotoxic lesion of the nigrostriatal pathway.

Authors:  David M Yurek; Anita M Fletcher; Laura E Peters; Wayne A Cass
Journal:  Neurochem Res       Date:  2010-04       Impact factor: 3.996

Review 10.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.